ConductScience.org, home

Paper41583504

POFUT2 Mediated Fucosylation of JUP Enhances VEGFA Expression to Promote Angiogenesis in Colorectal Cancer.

Zou Y and 4 others. Int J Med Sci, 2026. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. POFUT2 Mediated Fucosylation of JUP Enhances VEGFA Expression to Promote Angiogenesis in Colorectal Cancer. Papers, record 41583504. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41583504

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
POFUT2 Mediated Fucosylation of JUP Enhances VEGFA Expression to Promote Angiogenesis in Colorectal Cancer.
PubMed
Journal
Int J Med Sci
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-07-01
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zou YYanfeng
2Yang YYian
3Xu WWei
4Cao PPeiguo
5Li ZZheng

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Colorectal NeoplasmsMajor topic
Vascular Endothelial Growth Factor AMajor topic
Neovascularization, PathologicMajor topic
FucosyltransferasesMajor topic
Humans
Human Umbilical Vein Endothelial Cells
Gene Expression Regulation, Neoplastic
Prognosis
Cell Line, Tumor
Glycosylation
Female
Platelet Endothelial Cell Adhesion Molecule-1

Source PubMed

Download CSV of topics

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137683735AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.J Hepatol2023https://conductscience.org/library/papers/37683735PubMed
231905724Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment.J Clin Med2019https://conductscience.org/library/papers/31905724PubMed
329706631O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance.Cell Death Dis2018https://conductscience.org/library/papers/29706631PubMed
428430973Biological functions of fucose in mammals.Glycobiology2017https://conductscience.org/library/papers/28430973PubMed
522508695Anti-VEGF/VEGFR therapy for cancer: reassessing the target.Cancer Res2012https://conductscience.org/library/papers/22508695PubMed
635536554Comparison of Fucose-Specific Lectins to Improve Quantitative AFP-L3 Assay for Diagnosing Hepatocellular Carcinoma Using Mass Spectrometry.J Proteome Res2022https://conductscience.org/library/papers/35536554PubMed
731501519Endothelial CDS2 deficiency causes VEGFA-mediated vascular regression and tumor inhibition.Cell Res2019https://conductscience.org/library/papers/31501519PubMed
818421054Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.J Clin Oncol2008https://conductscience.org/library/papers/18421054PubMed
937353784m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma.Mol Cancer2023https://conductscience.org/library/papers/37353784PubMed
1037071094Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.JAMA2023https://conductscience.org/library/papers/37071094PubMed
1135739268Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.Nat Med2022https://conductscience.org/library/papers/35739268PubMed
1219884117Fucosylated glycan inhibition of human hepatocellular carcinoma cell migration through binding to chemokine receptors.Glycobiology2010https://conductscience.org/library/papers/19884117PubMed
1322427986Loss and recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions.PLoS One2012https://conductscience.org/library/papers/22427986PubMed
147806582E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton.J Cell Biol1994https://conductscience.org/library/papers/7806582PubMed
1525972125Glycosyltransferases involved in the synthesis of MUC-associated metastasis-promoting selectin ligands.Glycobiology2015https://conductscience.org/library/papers/25972125PubMed
1628391576Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.Invest New Drugs2017https://conductscience.org/library/papers/28391576PubMed
1735020204Cancer statistics, 2022.CA Cancer J Clin2022https://conductscience.org/library/papers/35020204PubMed
1837537172FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer.Cell Death Dis2023https://conductscience.org/library/papers/37537172PubMed
1933976130FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer.Nat Commun2021https://conductscience.org/library/papers/33976130PubMed
2038778217The OGT-c-Myc-PDK2 axis rewires the TCA cycle and promotes colorectal tumor growth.Cell Death Differ2024https://conductscience.org/library/papers/38778217PubMed

See all 46 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn Papers
42558900Fucose metabolism as a central axis linking inflammation, immunity, and cancer in the gut.Front Immunol2026https://conductscience.org/library/papers/42558900

Source PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AGO227161PubTator's text mininghttps://conductscience.org/library/genes/27161NCBI Gene
HSBP13281PubTator's text mininghttps://conductscience.org/library/genes/3281NCBI Gene
JUP3728PubTator's text mininghttps://conductscience.org/library/genes/3728NCBI Gene
PECAM15175PubTator's text mininghttps://conductscience.org/library/genes/5175NCBI Gene
POFUT223275PubTator's text mininghttps://conductscience.org/library/genes/23275NCBI Gene
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41583504

GET https://conductscience.org/api/papers/v1/41583504/references?page=2